Hikma Pharmaceuticals

Pharmaceuticals

HIK.L

GBX 1,712 1.2

Share price

$ 4.7 bn

Market Cap

$ 6 bn

Enterprise Value

Carbon footprint

GHG emissions per $ 1 mln investment

0.53x the weighted average for S&P 500

FY2021

Primary Climate Goal

Proj. YOY change in GHG emissions (Scope 1 + 2)

Weaker than the -6.6% weighted average for S&P 500

FY2022

Hikma Pharmaceuticals aims to reduce Scope 1 + 2 by 25% by 2030 from a base year 2020

This target is most likely outdated and the company appears to have already achieved it

This target has not been verified as science based according to SBTi

GHG emissions and Carbon intensity

Hikma Pharmaceuticals reported Total CO2e Emissions - Market-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2021 at 117 Kt (-28 /-19.5% y-o-y). Also positively, carbon intensity decreased to 46 t (-16 /-26.2% y-o-y).

Hikma Pharmaceuticals's Scope 3 emissions grew to 830 Kt (+829/+104124% y-o-y).

The company is committed to reducing Scope 1 + 2 by 25% by 2030 from a base year 2020, which it appears to have already achieved as of 2021. This target, however, has not been recognised as science-based (and as aligned with Paris Agreement) by the SBTi.

Date	Total CO2e emissions (market-based Scope 1 & 2) (Kt)	Scope 1	Scope 2	Scope 3	Revenue (USDm)	Carbon intensity (tons of CO2e) / (USDm)
2021Q4	117	41	76	830	2,553	46
2020Q4	145	47	98		2,341	62
2018Q4		38		0.8	2,070